Results 111 to 120 of about 12,412 (210)

A Matching-Adjusted Indirect Comparison of Guselkumab and Secukinumab in Patients with Psoriatic Arthritis Over 52 Weeks

Rheumatology and Therapy
Introduction Studies evaluating the long-term comparative efficacy between biologic therapies for psoriatic arthritis (PsA) are scarce. Two biologic therapies, guselkumab and secukinumab, were evaluated up to 52 weeks in a mixed patient population ...
Suzy van Sanden, Agata Schubert, Barkha P. Patel, Miriam Zimmermann, Fareen Hassan   +4 more
doaj   +1 more source

Delphi consensus: First‐line use of biologics and small molecules in hidradenitis suppurativa

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This Delphi Consensus study identified upgrade criteria for the use of biologics and small molecules as first‐line therapy in hidradenitis suppurativa (HS). European HS experts evaluated 16 clinical scenarios, voting on eligibility for therapy escalation.
Georgios Nikolakis, Erkan Alpsoy, Florian Anzengruber, Matthias Augustin, Falk G. Bechara, Pierre‐André Becherel, Farida Benhadou, Vincenzo Bettoli, Joana Cabete, Raffaele Dante Caposiena Caro, Antonella Di Cesare, Giovanni Damiani, Valentina Dini, Evangelos J. Giamarellos‐Bourboulis, Krisztián Gáspár, Katalin Glasenhardt, Philippe Guillem, Ariela Hafner, Barbara Horvath, John R. Ingram, Vaiva Jarienè, Gregor B. E. Jemec, Alexander Katoulis, Natalia Kirsten, Georgios Kokolakis, Piotr K. Krajewski, Aikaterini I. Liakou, Flavia Manzo Margiotta, Angelo V. Marzano, Antonio Martorell, Lukasz Matusiak, Dillon Mintoff, Alejandro Molina Leyva, Andreas Pinter, Anna Pirogova, Maurizio Podda, Francesca Prignano, Jorge Romani, Marco Romanelli, Elia Rosi, Samed Sahin, Ditte M. L. Saunte, Sylke Schneider‐Burrus, Mariano Suppa, Jacek Szepietowski, Andrea Szegedi, Simon Francis Thomsen, Thrasyvoulos Tzellos, Anastasia Trigoni, Hessel H. Van Der Zee, Kelsey Van Straalen, Skaidra Valiukevičiene, Eva Vilarrasa, Esther von Stebut, Christos C. Zouboulis   +54 more
wiley   +1 more source

Secukinumab Sustains Early Patient-Reported Outcome Benefits Through 1 Year: Results from 2 Phase III Randomized Placebo-Controlled Clinical Trials Comparing Secukinumab with Etanercept

, 2017
BACKGROUND: Psoriasis is a chronic condition with negative impact on patients\u27 quality of life that most often requires lifelong effective and safe treatment.
Sherif, B, McLeod, L, Papavassilis, C, Strober, B E, Fox, T, Mollon, P, Gilloteau, I, Mordin, M, Gottlieb, Alice, Gnanasakthy, A, Lebwohl, M   +10 more
core   +1 more source

Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study

, 2020
Background: Secukinumab is an interleukin-17A inhibitor used in the treatment of patients with active psoriatic arthritis. In the phase 3 FUTURE 2 trial, secukinumab showed sustained improvement in clinical outcomes over 2 years.
Pricop, Luminita, Kirkham, Bruce, Iain B McInnes, Bruce Kirkham, Philip J Mease, Sandra Navarra, Navarra, Sandra, Luminita Pricop, Proton Rahman, Rech, Jürgen, Philip G Conaghan, Kivitz, Alan J, Peter Nash, Conaghan, Philip G, Belsare, Ashwini D, Delicha, Eumoprhia M, Jürgen Rech, Alan J Kivitz, Mease, Philip J, Rahman, Proton, Eumoprhia M Delicha, Nash, Peter, Ashwini D Belsare, McInnes, Iain B, Mclnnes, Lain B   +24 more
core   +1 more source

Efficacy and Safety of Secukinumab in Treating Psoriasis Vulgaris

, 2022
Introduction. Plaque psoriasis (psoriasis vulgaris) is a chronic disease and the most common type of psoriasis. It is charactarized by well-defined areas with silvery scaling, erythema, puritus and sometimes pain. Psoriasis affects about 1.5 - 3 % of the
Pham, Randy
core   +1 more source

Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy

Dermatology Practical & Conceptual
Introduction: Risankizumab and secukinumab are effective treatment options for patients with moderate to severe psoriasis. Objective: We sought to estimate the efficacy and the cost per responder of risankizumab and secukinumab by comparing these two ...
Federico Pirro, Giacomo Caldarola, Nicoletta Bernardini, Maria Grazia Celeste, Annunziata Dattola, Eleonora De Luca, Marco Galluzzo, Domenico Giordano, Chiara Izzi, Giulia Maretti , Lorenzo Marcelli, Roberto Ravasio, Antonio Giovanni Richetta, Nevena Skroza, Marina Talamonti, Arianna Zangrilli, Luca Bianchi, Giovanni Pellacani, Severino Persechino, Concetta Potenza, Ketty Peris, Clara De Simone   +21 more
doaj   +1 more source

Long‐term efficacy of biologics in moderate‐to‐severe hidradenitis suppurativa: A systematic review and MAIC

Journal of the European Academy of Dermatology and Venereology, EarlyView.
A matching‐adjusted indirect treatment comparison (MAIC) was conducted, comparing approved biologics for long‐term (48–52 weeks) treatment of moderate‐to‐severe hidradenitis suppurativa (HS). Using weighted patient‐level trial data allowed re‐estimation of relative bimekizumab efficacy compared with aggregate secukinumab and adalimumab trial data ...
Thrasyvoulos Tzellos, Vincent Piguet, Michael Frank Mørup, Leah Davis, Vanessa Taieb, Sandeep Kiri, Victoria Shodimu, Abby Paine, Brian Kirby, Haley B. Naik   +9 more
wiley   +1 more source

Secukinumab demonstrates consistent safety over long-term exposure in patients with psoriatic arthritis and moderate to severe plaque psoriasis: updated pooled safety analyses

, 2018
Aims Pooled safety data from secukinumab psoriasis (PSO) and the psoriatic arthritis (PsA) clinical trial programs after about 1 year of exposure have been reported previously.
Mease, PJ, Nash, P, Abrams, K, Fox, T, Andersson, M, Reich, K, McInnes, IB, Pricop, L   +7 more
core   +1 more source

Severe hidradenitis suppurativa exacerbation in temporal association with PD‐1 blockade in cutaneous squamous cell carcinoma

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nadine Larissa Fergen, Konstantin Maria Steinke, Nicole Kreuzberg, Esther von Stebut, Cindy Franklin   +4 more
wiley   +1 more source

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The majority of bimekizumab‐treated patients shifted from severe to mild and moderate IHS4 stages, and nearly 25% achieved an IHS4 of 0 by Week 48. Bimekizumab led to clinically meaningful improvements across IHS4 outcome measures. These data highlight an opportunity to address the need for effective treatments against draining tunnels.
Thrasyvoulos Tzellos, Evangelos J. Giamarellos‐Bourboulis, Kelsey R. van Straalen, Antonio Martorell, Brian Kirby, Afsaneh Alavi, Koremasa Hayama, Saakshi Khattri, Wayne Gulliver, Christopher J. Sayed, Leah Davis, Robert L. Rolleri, Christina Crater, Ingrid Pansar, Jérémy Lambert, Christos C. Zouboulis   +15 more
wiley   +1 more source